Funding for this research was provided by:
National Cancer Institute (UM1 CA164920)
Cancer Australia (809195, 1100868)
National Health and Medical Research Council (454508, 288704, 145684)
National Institute of Health (1RO1CA159868)
National Institutes of Health, National Cancer Institute, Cancer Epidemiology Training Grant (T32-CA009529)
Text and Data Mining valid from 2019-04-18
Received: 20 December 2018
Accepted: 5 April 2019
First Online: 18 April 2019
Ethics approval and consent to participate
: All participants in the BCFR and kConFab provided written informed consent before participation. Human research ethics committees at the participating institutions granted ethics approval for the six sites of the BCFR and for kConFab:Northern California—Cancer Prevention Institute of California, Institutional Review Board (2001–033) and Stanford University School of Medicine, Institutional Review Board (45842).New York—Columbia University Medical Center, Institutional Review Board (AAA7794).Philadelphia—Fox Chase Cancer Center, Institutional Review Board (95–009).Utah—Huntsman Cancer Institute, University of Utah, Institutional Review Board (00004965).Ontario—Mount Sinai Hospital Research Ethics Board (#02–0076-U) and University Health Network Research Ethics Board (#96-U107-CE).Australia—University of Melbourne, Human Ethics Sub-Committee (1441420.1).kConFab—Peter MacCallum Cancer Centre, the Peter Mac Ethics Committee (97/27).
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.